The Role of Sphingolipid Metabolism in Pregnancy-Associated Breast Cancer After Chemotherapy
2024

Sphingolipid Metabolism in Pregnancy-Associated Breast Cancer After Chemotherapy

Sample size: 15 publication 10 minutes Evidence: moderate

Author Information

Author(s): Blokhin Victor, Zavarykina Tatiana, Kotsuba Vasily, Kapralova Maria, Gutner Uliana, Shupik Maria, Kozyrko Elena, Luzina Evgenia, Lomskova Polina, Bajgazieva Darya, Khokhlova Svetlana, Alessenko Alice, Wei Sainan, Di Jing

Primary Institution: Koltzov Institute of Developmental Biology of the Russian Academy of Sciences

Hypothesis

The study aims to determine the role of sphingolipids in the placenta of pregnant women with pregnancy-associated breast cancer after chemotherapy compared to healthy patients.

Conclusion

The study suggests that the placenta may protect against the toxic effects of chemotherapy in pregnant women with breast cancer, which could benefit the newborn.

Supporting Evidence

  • The expression of genes controlling sphingolipid metabolism was significantly altered in patients with pregnancy-associated breast cancer.
  • Patients with breast cancer showed increased expression of several key enzymes involved in sphingolipid metabolism.
  • No severe neonatal pathologies were detected in the newborns of the PABC group.
  • Premature labor was observed in 42.9% of patients with PABC.

Takeaway

This study looks at how certain fats in the body, called sphingolipids, might help protect pregnant women with breast cancer and their babies during chemotherapy.

Methodology

The study analyzed gene expression of sphingolipid metabolism enzymes and lipid content in placenta samples from patients with pregnancy-associated breast cancer and healthy controls using PCR and mass spectrometry.

Potential Biases

Potential biases may arise from the small sample size and the specific population studied.

Limitations

The study is limited by its small sample size and the need for further research to confirm findings.

Participant Demographics

The study included 7 patients with pregnancy-associated breast cancer and 8 healthy pregnant women, with a median age of 27.5 years in the control group.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3390/biomedicines12122843

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication